Paris system of reporting urine cytology: An important screening tool for urothelial neoplasms

Abstract

Urine cytology is an important screening tool for detection of high grade urothelial carcinoma and follow-up of patients with treated disease. Ease of procurement, cost-effectiveness, and lower turnaround time are the major advantages of the system. We aim to determine the frequency of high grade and low grade urothelial carcinoma in urine cytology specimens and to evaluate the accuracy of Paris system. A retrospective study was conducted in the Department of Pathology (Cytology), GMCH from August 2020 to July 2022 where a total of 200 cases were included. Data along with the preserved slides of urine cytology of these cases were collected from the archives and examined for the presence of urothelial carcinoma. The results were calculated in Microsoft word and excel, and p value was calculated by using the Chi- square (χ2) test of significance, P values less than 0.05 was considered statistically significant. In our study, a total of 200 cases were analysed, 169 were males and 31 were females, the male to female ratio being 5.5: 1. The most commonly affected age group was 61-70 years, the mean age being 62 years. Of the 200 urine samples examined, 12.5% cases had High Grade Urothelial Carcinoma (HGUC), 13.5% cases had atypical urothelial cells, 9% cases were suspicious for HGUC and 2% cases had Low Grade Urothelial Neoplasm. : The Paris System is a highly sensitive and rapid tool for reporting urine cytology specimens and is particularly useful in diagnosing High Grade Urothelial Carcinoma thereby helping in early management of the patients with neoplastic lesions of the urinary bladder.